ISIS 2302: Started Phase I trial in the U.K.

Isis Pharmaceuticals Inc. (ISIP), Carlsbad, Calif. Product: ISIS 2302, antisense oligonucleotide to inhibit expression of ICAM-1 (intracellular adhesion molecule-1) Indication: Organ transplant, pso...